RxDoctor Payments Data

Michal Gerblich

Family · Harrison, NYNPI 1770012429

Payments from drug & device makers

$5,505in general payments, 2019–2025

Across 277 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$397
  • Ardelyx, Inc.$366
  • Ironwood Pharmaceuticals, Inc$305
  • Novo Nordisk$250
  • plus $475 from 7 others

What the payments were for

  • Food & beverage$5,505100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,505 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$64,883
Medicare patients
423
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide84$85,267
CreonLipase/Protease/Amylase18$45,586
SutabSod Sulf/Pot Chloride/Mag Sulf44$6,938
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates106$6,455
Famotidine282$4,042
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag19$2,274
Omeprazole194$1,862
Pantoprazole Sodium71$1,077
Rabeprazole Sodium12$647
Hydrocortisone30$501
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl18$255
Dicyclomine Hcl13$125
Ondansetron OdtOndansetron11$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,459$130,854102 claims
Braintree Laboratories, Inc.Sutab, Suflave$63$9,21263 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Harrison

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →